February 2026 brought a wave of clinical evidence that moves the conversation in aesthetic medicine from trend awareness to data-informed decision-making. From a landmark head-to-head neurotoxin comparison to new quantifiable metrics on GLP-1-related facial volume loss, this month’s research gives physicians and nurse practitioners a stronger foundation for protocol development, patient counseling, and practice growth.

Every profitable aesthetic practice is built on three core services: injectables, lasers, and facial rejuvenation. Learn which service to start with, how much revenue each generates, and how to expand strategically as your practice grows.

A new 2026 study published in the Journal of Cosmetic Dermatology reveals how combining Microneedle Fractional Radiofrequency (MFR) with Platelet-Rich Plasma (PRP) offers targeted advantages for treating complex melasma. For providers entering aesthetic medicine, this research demonstrates why advanced combination therapies are essential for building a modern, profitable practice beyond basic injectables.

Letybo, South Korea’s #1 neurotoxin, has officially launched in the U.S., offering providers a faster-onset alternative to Botox with a competitive price point. This comprehensive guide breaks down how Letybo compares to Botox and Daxxify, who makes an ideal candidate, and whether this new product deserves a place in your practice.

The neurotoxin market is segmenting by duration, offering providers options from 2-3 weeks to 6 months for personalized patient care. January 2026 also brought Level 1 evidence for neck rejuvenation, clinical data on regenerative approaches, and FDA clearances expanding aesthetic devices into medical applications.

Treating platysma bands with neurotoxins represents a significant opportunity for aesthetic practitioners to differentiate their expertise beyond traditional facial injections. However, mastering this advanced neck rejuvenation technique requires comprehensive training in complex anatomy, risk management, and patient selection to ensure safe, effective outcomes.

October 2025 brought major regulatory and clinical updates shaping aesthetic medicine—from the FDA’s RF microneedling alert to new neurotoxin and device approvals. These developments highlight how evidence-based innovation and patient education are redefining safe, inclusive, and profitable practice growth.